Veltassa

RSS

patiromer

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Veltassa. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Veltassa.

For practical information about using Veltassa, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 03/04/2023

Authorisation details

Product details
Name
Veltassa
Agency product number
EMEA/H/C/004180
Active substance
patiromer sorbitex calcium
International non-proprietary name (INN) or common name
patiromer
Therapeutic area (MeSH)
Hyperkalemia
Anatomical therapeutic chemical (ATC) code
V03AE09
Publication details
Marketing-authorisation holder
Vifor Fresenius Medical Care Renal Pharma France
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
19/07/2017
Contact address

100-101 Terrasse Boieldieu
Tour Franklin La Defense 8
Paris La Defense
Cedex 92042
Paris
France

Product information

24/02/2023 Veltassa - EMEA/H/C/004180 - IA/0032/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs for treatment of hyperkalemia and hyperphosphatemia

Therapeutic indication

Veltassa is indicated for the treatment of hyperkalaemia in adults.

Assessment history

Related content

How useful was this page?

Add your rating